Supernus Pharmaceuticals
SUPN
166 hedge funds and large institutions have $725M invested in Supernus Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 58 increasing their positions, 29 reducing their positions, and 23 closing their positions.
204% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 23
100% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 29
48% more capital invested
Capital invested by funds: $491M → $725M (+$234M)
39% more funds holding
Funds holding: 119 → 166 (+47)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
9% more call options, than puts
Call options by funds: $3.52M | Put options by funds: $3.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$20.9M |
| 2 |
ACM
Apex Capital Management
Dayton,
Ohio
|
+$19.6M |
| 3 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$17.8M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$16M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$9.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$43.1M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$42.8M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$27.8M |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$11.9M |
| 5 |
MRM
Michael R. Murphy
|
-$11M |
SUPN Hedge Fund Activity: Q2 2015 in Review
166 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2015, worth a combined $725M — up 48% from $491M a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new SUPN positions and 23 closed out — a net gain of 47 holders — while 58 added to existing stakes and 29 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $20.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $43.1M sold.
- 166 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2015, up from 119 in Q1 2015.
- Funds reported $725M of Supernus Pharmaceuticals stock for Q2 2015, up 48% quarter-over-quarter.
- 70 funds opened new Supernus Pharmaceuticals positions in Q2 2015 and 23 closed out, a net change of +47 holders.
- The largest Supernus Pharmaceuticals buyer in Q2 2015 was Invesco, an estimated $20.9M added.
- The largest Supernus Pharmaceuticals seller in Q2 2015 was Consonance Capital Management, an estimated $43.1M sold.
Based on aggregated 13F filings for Q2 2015.